CURRENT TOPIC

Fibrosing colonopathy in cystic fibrosis

Rosalind L Smyth

In 1994, the first case reports of colonic strictures (now referred to as fibrosing colonopathy) in children with cystic fibrosis appeared in the medical literature.1-5 The initial case reports described patients who presented with intestinal obstruction and required surgical resection of a thickened and narrowed area of colon.1 The only aspect of these children’s management that had changed was a switch to new ‘high strength’ pancreatic enzyme preparations about 12 months previously. It was suggested that use of these preparation may be associated with this condition. Abdominal complaints occur frequently in cystic fibrosis; for example the incidence of Crohn’s disease has been reported to be 17 times higher than the general population.6 It was not clear initially whether these cases represented variations of the normal pathology reported in cystic fibrosis, or a new entity. In some instances, the clinical and radiological features were suggestive of Crohn’s disease, or an inflammatory colitis, but the histological findings were strikingly different. It is the pathological findings (described below), not reported previously in cystic fibrosis, which have characterised this condition. I will attempt to review the clinical, radiological, and histological features of this condition and discuss the current evidence on aetiology.

Clinical features
The clinical presentation of fibrosing colonopathy is non-specific. Abdominal pain, distension, vomiting, and constipation are frequent features7 and have led initially to confusion with distal intestinal obstruction syndrome.8 However, these symptoms fail to respond to the usual medical management of distal intestinal obstruction syndrome and the patient may progress to subacute and later acute obstruction. Children have also presented with symptoms of a colitis, with diarrhoea, sometimes containing blood and mucus, abdominal pain, and anorexia.5 Ascites has been reported and chylous ascites has been evident in some patients at operation4 (R Nelson, personal communication). The reasons for this last observation are not entirely clear, although it has been suggested that there may have been obstruction of mesenteric lymphatic vessels. The onset of symptoms may be insidious, over many months, so prompt investigation of children presenting with any of these symptom complexes is clearly advisable.

The decision about when to operate may not be straightforward, except in children who have large bowel obstruction. Some children have been operated on because of intractable diarrhoea, faecal incontinence, anorexia, and weight loss.4,5 In a number of children who presented with evidence of extensive involvement of the colon, defunctioning ileostomies have been performed in the hope that by diverting faeces from the colon some of the changes may resolve and a more limited resection may subsequently be undertaken. The experience in some of these cases has been that rather than improving, the narrowing has progressed and become more extensive,7 rendering subsequent surgery more difficult. I am aware of a number of children who have presented with diffuse involvement of the colon, and in whom resection or ileostomy has been avoided. These children have remained well on conservative management. It would therefore seem wise to manage these children conservatively where possible, but with very careful clinical monitoring and annual ultrasound to assess bowel wall thickness.

Radiological features
A thickened colon wall may be evident on plain abdominal radiograph and may be confirmed by ultrasonography. The features of fibrosing colonopathy on ultrasound include bowel wall thickening of more than 2 mm,9 reduced peristalsis, and free fluid associated with the affected areas.10 We investigate all children who present with abdominal pain with an abdominal radiograph and bowel ultrasound. Distal intestinal obstruction syndrome is the most frequent finding.11 If both are normal, then fibrosing colonopathy is very unlikely.12 If there are any of the above abnormalities on ultrasound, then contrast studies are indicated. The findings on contrast enema fall into to main groups.13 In the first, the intraluminal widening causes a localised narrowing of the colon without mucosal abnormality. There may be evidence of obstruction. The main differential diagnosis is Crohn’s disease. The second group of patients have evidence of more extensive colonic inflammation, loss of haustration, and marked mucosal abnormality. The differential diagnosis is wide and includes fibrosing colonopathy, Crohn’s disease, ulcerative colitis, pseudomembranous of infective colitis.
Fibrosing colonopathy is a histopathological diagnosis and requires either a resection specimen or a full thickness biopsy. Not all patients believed to have this condition have required surgery and suitable biopsy material can be obtained only by laparotomy. Colonoscopic biopsies, which usually sample the mucosa alone, are generally unsatisfactory. One is therefore left with the difficult situation of trying to identify the condition by clinical and radiological criteria. Because of the range of possible differential diagnoses, even after all imaging has been completed I believe that definitive diagnosis is not possible in such cases.

The histopathological features are pathognomonic. The stenoses, which are frequently long segment, result from submucosal thickening by fibrous connective tissue. This leads to intraluminal narrowing which occurs without a significant reduction in the external diameter of the colon. The epithelium is generally intact with very little inflammatory change in the affected areas. In the original report of this condition the patients were described as having a localised stricture in the ascending colon, although after surgical resection, one patient subsequently developed a second stricture, suggesting that the disorder may have been more widespread that originally suspected. Other reports have described patients with extensive fibrosis throughout the colon at presentation. To emphasise the long segment colonic involvement and the distinction between this condition and inflammatory strictures that are typically focal, the term fibrosing colonopathy is now used in preference to 'colonic strictures'.

Aetiology of fibrosing colonopathy

The first reports of fibrosing colonopathy and the suggested link with high strength pancreatic enzyme products came like a bombshell. Regulatory authorities moved swiftly on both sides of the Atlantic. In the UK, the Committee on Safety of Medicines recommended that patients being treated with high strength pancreatic enzyme preparations should be reviewed and unless there were special reasons they should be changed back to standard strength preparations. In the USA the situation was more complex. A wide range in strengths of pancreatic enzyme products was available. Because they were already on the market in the USA in 1938, before the Food Drug and Cosmetic Act, these products had not undergone the usual safety and efficacy studies. The Food and Drugs Administration requested withdrawal of products containing more than 20,000 units of lipase and called for standard testing of pancreatic products.

Shortly after the first reports of fibrosing colonopathy, in the UK, epidemiological studies were designed firstly to establish the incidence of this condition in the cystic fibrosis population in the country, secondly to determine if it was a new entity, and finally to identify factors with which it was associated. A cohort evaluation was initiated to address the first two of these aims. Details were requested of all cystic fibrosis patients who had undergone surgery in between 1984 and 1994. Where small or large bowel had been resected or biopsied, the histological sections were reviewed. It was well recognised that a number of cases had presented with clinical and radiological features of fibrosing colonopathy, but had not required surgery and histological material was not therefore available. Because the diagnosis in these cases was less precise, it was decided not to include them in the case-control study. From twelve cases of fibrosing colonopathy were identified, the first occurring in April 1993. Twelve were boys and six had received some or all of their care in Liverpool. A nested case-control study was then undertaken, where each case was matched by date of birth with four controls taken from the UK cystic fibrosis survey. The case-control studied identified an association between fibrosing colonopathy and use of high strength pancreatic enzyme preparations, but not the use of low strength preparations. The association with high strength preparations was dose related, temporally credible, and biologically plausible but was not high strength preparations were, however, found to be associated. Two similar products, Pancrease HL (Cilag) and Nutrizym 22 (Merck) were found to be associated with fibrosing colonopathy, but Creon 25000 (Duphar) was not.

The study also demonstrated that cases were more likely than controls to have taken laxatives in the 12 months before surgery. A possible explanation for this was that when patients with fibrosing colonopathy initially presented they had abdominal pain. Some were thought to have distal intestinal obstruction syndrome and were therefore treated with laxatives. This illustrates the difficulty of inferring causality on the basis of an association demonstrated in an observational case-control study.

There were two main hypotheses generated from this case-control study. The first was that the disorder is due to one of the active constituents of pancreatic enzyme preparations. The use of high strength enzyme preparations would enable much larger doses of such an active constituent to be delivered to the colon. If this hypothesis were correct, this condition may occur if sufficiently large doses of low strength preparations were taken. An alternative hypothesis is that the disorder is due to an excipient present in the enteric coating of the microencapsulated preparations, which damages the colon in a dose dependent manner. Creon 35000 is formulated as microspheres, which are heterogenous in size; Pancrease HL and Nutrizym 22 are formulated as minitablets which are of uniform size. Eudragit-L, one of the components of the minitablet coating, is a copolymer based on methacrylic acid and ethyl acrylate. These compounds have been shown to have a toxic effect on the gut of experimental animals. It has been suggested that the methacrylic acid copolymer present in the enteric coating

Pathological diagnosis

Fibrosing colonopathy is a histopathological diagnosis and requires either a resection specimen or a full thickness biopsy. Not all patients believed to have this condition have required surgery and suitable biopsy material can be obtained only by laparotomy. Colonoscopic biopsies, which usually sample the mucosa alone, are generally unsatisfactory. One is therefore left with the difficult situation of trying to identify the condition by clinical and radiological criteria. Because of the range of possible differential diagnoses, even after all imaging has been completed I believe that definitive diagnosis is not possible in such cases.

The histopathological features are pathognomonic. The stenoses, which are frequently long segment, result from submucosal thickening by fibrous connective tissue. This leads to intraluminal narrowing which occurs without a significant reduction in the external diameter of the colon. The epithelium is generally intact with very little inflammatory change in the affected areas. In the original report of this condition the patients were described as having a localised stricture in the ascending colon, although after surgical resection, one patient subsequently developed a second stricture, suggesting that the disorder may have been more widespread that originally suspected. Other reports have described patients with extensive fibrosis throughout the colon at presentation. To emphasise the long segment colonic involvement and the distinction between this condition and inflammatory strictures that are typically focal, the term fibrosing colonopathy is now used in preference to 'colonic strictures'.

Aetiology of fibrosing colonopathy

The first reports of fibrosing colonopathy and the suggested link with high strength pancreatic enzyme products came like a bombshell. Regulatory authorities moved swiftly on both sides of the Atlantic. In the UK, the Committee on Safety of Medicines recommended that patients being treated with high strength pancreatic enzyme preparations should be reviewed and unless there were special reasons they should be changed back to standard strength preparations. In the USA the situation was more complex. A wide range in strengths of pancreatic enzyme products was available. Because they were already on the market in the USA in 1938, before the Food Drug and Cosmetic Act, these products had not undergone the usual safety and efficacy studies. The Food and Drugs Administration requested withdrawal of products containing more than 20,000 units of lipase and called for standard testing of pancreatic products.

Shortly after the first reports of fibrosing colonopathy, in the UK, epidemiological studies were designed firstly to establish the incidence of this condition in the cystic fibrosis population in the country, secondly to determine if it was a new entity, and finally to identify factors with which it was associated. A cohort evaluation was initiated to address the first two of these aims. Details were requested of all cystic fibrosis patients who had undergone surgery in between 1984 and 1994. Where small or large bowel had been resected or biopsied, the histological sections were reviewed. It was well recognised that a number of cases had presented with clinical and radiological features of fibrosing colonopathy, but had not required surgery and histological material was not therefore available. Because the diagnosis in these cases was less precise, it was decided not to include them in the case-control study. From twelve cases of fibrosing colonopathy were identified, the first occurring in April 1993. Twelve were boys and six had received some or all of their care in Liverpool. A nested case-control study was then undertaken, where each case was matched by date of birth with four controls taken from the UK cystic fibrosis survey. The case-control studied identified an association between fibrosing colonopathy and use of high strength pancreatic enzyme preparations, but not the use of low strength preparations. The association with high strength preparations was dose related, temporally credible, and biologically plausible but was, however, found to be associated. Two similar products, Pancrease HL (Cilag) and Nutrizym 22 (Merck) were found to be associated with fibrosing colonopathy, but Creon 25000 (Duphar) was not.

The study also demonstrated that cases were more likely than controls to have taken laxatives in the 12 months before surgery. A possible explanation for this was that when patients with fibrosing colonopathy initially presented they had abdominal pain. Some were thought to have distal intestinal obstruction syndrome and were therefore treated with laxatives. This illustrates the difficulty of inferring causality on the basis of an association demonstrated in an observational case-control study.

There were two main hypotheses generated from this case-control study. The first was that the disorder is due to one of the active constituents of pancreatic enzyme preparations. The use of high strength enzyme preparations would enable much larger doses of such an active constituent to be delivered to the colon. If this hypothesis were correct, this condition may occur if sufficiently large doses of low strength preparations were taken. An alternative hypothesis is that the disorder is due to an excipient present in the enteric coating of the microencapsulated preparations, which damages the colon in a dose dependent manner. Creon 35000 is formulated as microspheres, which are heterogenous in size; Pancrease HL and Nutrizym 22 are formulated as minitablets which are of uniform size. Eudragit-L, one of the components of the minitablet coating, is a copolymer based on methacrylic acid and ethyl acrylate. These compounds have been shown to have a toxic effect on the gut of experimental animals. It has been suggested that the methacrylic acid copolymer present in the enteric coating
of some preparations may be causal factor in
the aetiology of fibrosing colonopathy.20 This
hypothesis would explain the association with
high strength preparations, and the difference
in association between different high strength
products. Indirect evidence in support of the
second hypothesis has come from two further
observations. The first is that two, histolog-
ically confirmed, cases of fibrosing colonopathy
have been described in young children treated
with the low strength preparation Nutrizym
GR (Merc).20 21 Nutrizym GR is one of the
few low strength preparations that contains the
methylacrylic acid copolymer.20 The second
observation was reported recently by Croft et
al, who used the technique of whole gut
lavage to study gut inflammation in patients
with cystic fibrosis receiving high strength pan-
cratic enzyme preparations.22 They found that
two patients, who were both taking Nutrizym
22, had strikingly abnormal results indicative
of severe mucosal inflammation.
Clearly there is still uncertainty about the
aetiology of fibrosing colonopathy and further
work is needed to investigate both of the
hypotheses described above. The Committee
on Safety of Medicines has considered the
results of the case-control study and has recom-
mented that Pancrease HL and Nutrizym 22 are not used in children under the
age of 15 years. They have also suggested that
it would be prudent to avoid total daily doses
of enzyme supplementation above 10 000 units
of lipase/kilogram/day.23 In the USA, a recent
consensus committee has made similar recom-
mandations, advocating a maximum dose of
2500 units of lipase/kilogram/meal.24

Conclusion
The introduction of enteric coated pancreatic
enzyme supplements in the early 1980s was
undoubtedly one of the major advances in the
care of children with cystic fibrosis. Further
refinements in the presentation of these prepa-
rations inevitably followed, to improve patient
acceptability and compliance. The emergence of
fibrosing colonopathy took clinicians deal-
ing with cystic fibrosis completely by surprise,
and in the last two years there has been a grad-
ual appreciation that as far as pancreatic
enzyme products are concerned ‘More is not
necessarily better’.10 However, it is encourag-
ing that, in the UK, there have been no histo-
ologically confirmed cases in children receiving
high strength pancreatic enzyme preparations
since July 1994. Hopefully this trend will
continue and the causal factors will be defined,
ensuring that this serious complication can be
effectively prevented in the future.

1 Smyth RL, Van Velzen D, Smyth AR, Lloyd DA, Heaf DP.
Screening of ascending colon in cystic fibrosis and high-
2 Oades PJ, Bush A, Ong PS, Berrettoni RJ. High strength pan-
cratic enzyme supplements and large-bowel stricture in
3 Campbell CA, Forrest J, Musgrove C. High strength pan-
cratic enzyme supplements and large bowel stricture in
4 Zerin JM, Kuhn-Falton J, White SJ. Colonic strictures in
children with cystic fibrosis. Radiology 1995; 194:
223–6.
changes of the colon in cystic fibrosis and high-strength
6 Lloyd-Still JD. Crohn’s disease and cystic fibrosis. Dig Dis
7 Zerin JM, Kuhn-Falton J, White SJ, et al. Colonic strictures
in children with cystic fibrosis. Radiology 1995; 194:
223–6.
8 Roseman BJ, Langbaum TS. Incidence of distal intestinal
obstruction syndrome in cystic fibrosis. J Pediatr
9 MacSweeney EJ, Oades PJ, Buchdahl R, Roseman M,
Bush A. Relation of thickening of colon wall to pancreatic
enzyme treatment in cystic fibrosis. Lancet 1995; 345:
752–5.
10 Taylor CJ. Commentary: colonic strictures in cystic fibrosis.
11 Carty H. Abdominal radiology in cystic fibrosis. J R Soc
12 Smyth RL, Carty H, Heaf DP. Colonic strictures in cystic
13 Franklin A, Oates PJ, Bush A. Colonic strictures in cystic
in cystic fibrosis: results of a case-control study. Lancet
15 Committee on Safety of Medicines, Medicines Control
Agency. Update: bowel strictures and high-potency pan-
cratic enzymes. Current Problems in Pharmacovigilance
16 Lebenthal E. High strength pancreatic exocrine enzyme
capsules associated with colonic strictures in patients with
cystic fibrosis: ‘More is not necessarily better’ [Editorial].
17 Lloyd-Still JD. Cystic fibrosis and colonic strictures. A new
18 Treon JP, Signmon H, Wright K, Kitzmiller KV. The toxici-
ity of methyl and ethyl acrylate. Journal of Industrial
Hygiene and Toxicology 1949; 31: 317–26.
19 Ghazavemi BI, Maronpot RR, Matthews HB. Ethyl acry-
late-induced gastric toxicity. I Effect of single and repeti-
20 Van den Ende J. Colonic complications in children with
cystic fibrosis on low-strength pancreatic enzymes. Lancet
21 Jones R, Franklin K, Spicer R, Berry J. Colonic strictures
in children with cystic fibrosis on low-strength pancreatic
22 Croft NM, Marshall TG, Ferguson A. Gut inflammation in
children with cystic fibrosis on high-dose enzyme supple-
23 Committee on Safety of Medicines, Medicines Control
Agency. Fibrosing colonopathy associated with pancreatic
11.
24 Borowicz DS, Grand RJ, Durie P and the Committee
Consensus. Use of pancreatic enzyme supplements for
patients with cystic fibrosis in the context of fibrosing

Commentary
Implications of the Committee on Safety of Medicines 10 000 IU lipase/kg/day
recommendation for use of pancreatic enzymes in
fibrosing cystic fibrosis
The latest recommendation of the Committee
on Safety of Medicines that ‘it would be
prudent to avoid doses of pancreatic enzyme
supplements in excess of 10 000 units of
lipase/kg/day, irrespective of the preparation’
has caused a problem for paediatricians
who have cystic fibrosis patients, many of whom
are taking considerably more enzymes than recom-
manded. Most patients have reached their
present dose by increasing the number of enzymes
to a level sufficient to control their gastro-
intestinal symptoms and signs. In some
patients the symptoms may not have been
caused by their intestinal malabsorption and
the increase in dose is inappropriate and results
in their taking an excessive dose of enzymes.
However, there are many others who certainly
do require more than the recommended
10 000 units of lipase/kg/day to control both
their symptoms and their fat malabsorption.
Unfortunately both must be monitored, as
symptoms can occur with normal fat absor-
ption, and severe malabsorption may occur
without any symptoms.
Fibrosing colonopathy in cystic fibrosis.

R L Smyth

Arch Dis Child 1996 74: 464-468
doi: 10.1136/adc.74.5.464

Updated information and services can be found at:
http://adc.bmj.com/content/74/5/464

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/